EA201492148A1 - Способ лечения немелкоклеточного рака легких - Google Patents

Способ лечения немелкоклеточного рака легких

Info

Publication number
EA201492148A1
EA201492148A1 EA201492148A EA201492148A EA201492148A1 EA 201492148 A1 EA201492148 A1 EA 201492148A1 EA 201492148 A EA201492148 A EA 201492148A EA 201492148 A EA201492148 A EA 201492148A EA 201492148 A1 EA201492148 A1 EA 201492148A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lung cancer
cell lung
patient
inoperable
nucleotides
Prior art date
Application number
EA201492148A
Other languages
English (en)
Russian (ru)
Inventor
Чен Дуксин
Шоши Тесслер
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201492148A1 publication Critical patent/EA201492148A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201492148A 2012-05-18 2013-05-17 Способ лечения немелкоклеточного рака легких EA201492148A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
EA201492148A1 true EA201492148A1 (ru) 2015-04-30

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492148A EA201492148A1 (ru) 2012-05-18 2013-05-17 Способ лечения немелкоклеточного рака легких

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300257T3 (es) 1999-02-26 2008-06-16 The University Of British Columbia Terapia antisentido contra trpm-2.
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
ES3041855T3 (en) 2010-05-08 2025-11-17 Univ California Radiofrequency sensing method and apparatus for early detection of pressure ulcers
WO2012123823A1 (en) 2011-03-15 2012-09-20 The University Of British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA2982249C (en) 2015-04-24 2019-12-31 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
SG11201810082VA (en) * 2016-05-13 2018-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
DK3515306T3 (da) 2017-02-03 2025-01-27 Bbi Medical Innovations Llc Måling af modtagelighed for diabetiske fodsår
PT3515296T (pt) 2017-02-03 2023-12-18 Bbi Medical Innovations Llc Medição da viabilidade do tecido
JP6900477B2 (ja) 2017-02-03 2021-07-07 ブルーイン、バイオメトリクス、リミテッド、ライアビリティー、カンパニーBruin Biometrics, Llc コンパートメント症候群を評価するための装置、およびコンパートメント症候群を検出するためのコンピュータ可読媒体
AU2018368709C1 (en) * 2017-11-16 2025-07-17 Bruin Biometrics, Llc Providing a continuity of care across multiple care settings
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
SI3749181T1 (sl) 2018-02-09 2024-06-28 Bruin Biometrics, LLC, Odkrivanje poškodb na tkivu
CN117596814A (zh) 2018-10-11 2024-02-23 布鲁恩生物有限责任公司 具有一次性元件的装置
WO2022169850A1 (en) 2021-02-03 2022-08-11 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
MX2010014228A (es) * 2008-06-18 2011-03-29 Abbott Laboratories Star Metodos y productos de diagnostico del p/gf-1 acompañante.
EP2709673A4 (en) * 2011-05-19 2014-12-17 Teva Pharma METHOD FOR THE TREATMENT OF NON-SMALL CELLULAR CANCER

Also Published As

Publication number Publication date
CN104684564A (zh) 2015-06-03
EP2849761A1 (en) 2015-03-25
KR20150024843A (ko) 2015-03-09
AU2013262589A1 (en) 2015-01-22
WO2013173757A8 (en) 2015-04-30
CA2874092A1 (en) 2013-11-21
BR112014028787A2 (pt) 2017-06-27
US20130310440A1 (en) 2013-11-21
UY34812A (es) 2013-12-31
JP2015522542A (ja) 2015-08-06
PH12014502569A1 (en) 2015-01-21
TW201402132A (zh) 2014-01-16
AR091090A1 (es) 2014-12-30
IN2014DN10390A (enExample) 2015-08-14
IL235459A0 (en) 2014-12-31
WO2013173757A1 (en) 2013-11-21
SG11201407649RA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
EA201492148A1 (ru) Способ лечения немелкоклеточного рака легких
MX2013013384A (es) Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.
MX359548B (es) Agentes de iarn modificados.
AR125906A2 (es) Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento del cáncer
BR112013005872A2 (pt) compostos, composição farmacêutica e respectivos usos
RU2014101547A (ru) Апоптоз-индуцирующее средство
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
MX2013009191A (es) Oligonucleotidos antisentido.
RU2019130513A (ru) Антисмысловые нуклеиновые кислоты
EA201790420A1 (ru) Средства, представляющие собой модифицированную двухнитевую рнк
BR112015009559A2 (pt) uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
MX365365B (es) Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
EA201171415A1 (ru) Ингибиторы белков семейства iap
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
JP2014521342A5 (enExample)
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells
BRPI0612334A2 (pt) uso de uma abordagem baseada em galectina-1 direcionada para rnai no tratamento do cÂncer
BR112013006541A2 (pt) agente preventivo ou terapêutico para fibrose
WO2012078648A3 (en) Novel method of cancer diagnosis and prognosis and prediction of response to therapy